Breaking News

Tweet TWEET

In Terms of Effect on Overall Survival, Current and Emerging Therapies Have No Advantage Over Avastin/FOLFIRI in the Treatment

In Terms of Effect on Overall Survival, Current and Emerging Therapies Have No
  Advantage Over Avastin/FOLFIRI in the Treatment of Second-Line Metastatic
   Colorectal Cancer, According to Clinical Data and Thought Leader Opinion

No Late-Stage Emerging Therapies are Likely to Impact Overall Survival, Which
is One of the Greatest Unmet Needs in the Indication, According to a New
Report from Decision Resources

PR Newswire

BURLINGTON, Mass., July 15, 2013

BURLINGTON, Mass., July 15, 2013 /PRNewswire/ --Decision Resources, one of
the world's leading research and advisory firms for pharmaceutical and
healthcare issues, finds that the effect of a therapy on overall survival and
progression-free survival are attributes that most influence surveyed U.S. and
European oncologists' prescribing decisions for second-line metastatic
colorectal cancer. Clinical data and the opinions of interviewed thought
leaders, however, indicate that current and emerging therapies have no
advantage over the sales-leader bevacizumab (Genentech/Roche/Chugai's
Avastin)/FOLFIRI (5-fluorouracil, leucovorin and irinotecan) on overall
survival, one of the greatest unmet needs in second-line metastatic colorectal
cancer. However, opinion leaders express optimism that clinical trial data
could show that the mechanism of action of Eli Lilly/ImClone's ramucirumab
could confer a benefit on progression-free survival.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The Decision Base 2013 report entitled As the Second-Line Treatment Setting
for Colorectal Cancer Becomes More Crowded, How Will Oncologists and Payers
Differentiate Among New Therapies? finds that surveyed U.S. oncologists would
prescribe ramucirumab, in combination with FOLFIRI, to a median of 20 percent
of their second-line drug-treated, metastatic colorectal cancer patients. This
modest patient share demonstrates the struggle that a new agent will face
penetrating the familiarity of Avastin, as well as strong competition from
aflibercept (Sanofi/Regeneron's Zaltrap) and regorafenib (Bayer Healthcare's
Stivarga), the latter of which is currently used primarily in later lines of
treatment.

The findings also reveal that the safety and tolerability of second-line
therapies for metastatic colorectal cancer are another important consideration
in oncologists' prescribing decisions, as the incidence of  colorectal cancer
increases with age and, as a result, therapies in this setting have a great
impact on the quality of life in an elderly population.

The report also finds that surveyed managed care organization (MCO) pharmacy
directors are receptive to novel therapies that offer an improvement in median
overall survival over currently available therapies, but while some emerging
therapies hold promise, they are unlikely to match payers' requirements for
widespread inclusion on their formularies.

"Avastin in combination with FOLFIRI is currently the most widely used regimen
for the second-line treatment of metastatic colorectal cancer," said Decision
Resources Business Insights Analyst Dana Gheorghe, Ph.D. "An emerging therapy
like ramucirumab will find it difficult to penetrate the already crowded
second-line market, given physicians' familiarity with Avastin. However, if
ramucirumab can show competitive advantages in efficacy, and safety in Phase
III trials, we believe it has the potential to compete strongly following its
anticipated launch in 2015."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market
research publications, advisory services and consulting designed to help
clients shape strategy, allocate resources and master their chosen markets.
Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers
best-in-class, high-value information and insights on important sectors of the
healthcare industry. Clients rely on this analysis and data to make informed
decisions. Please visit Decision Resources Group at
www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be
trademarks or registered trademarks of their respective holders.

SOURCE Decision Resources

Website: http://www.decisionresources.com
Contact: Decision Resources Group, Christopher Comfort, 781-993-2597 ,
ccomfort@dresources.com